Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Are protests pushing Iran's Islamic regime toward a tipping point? - 2Individual Preparation Administrations to Raise Your Wellness Process
- 3Language Learning Stages: Which One Gets Your Vote?
- 4Unwinding History's Secrets: Looking for the Response to Antiquated Human advancements
- 5Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- Bolsonaro briefly leaves Brazilian prison for medical tests after a fall from his bed
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- Pick Your Favored kind of sandwich
- Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet
- Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- Palestinians tell BBC they were sexually abused in Israeli prisons
- Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- Step by step instructions to Remain Spurred While Chasing after a Web-based Degree
- Desired Travel Objections Worldwide: Where to Go Straightaway
